ERBB2 and neoplasm: Song et al. observed that a subtherapeutic dose of trastuzumab (4 mg/kg) significantly reduced tumor hypoxia by 30% and increased innate immune cell activation when combined with radiotherapy in HER2+ primary breast cancer16.